Iguana Healthcare Management LLC bought a new stake in FibroGen Inc (NASDAQ:FGEN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 40,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,152,000.
Other institutional investors have also added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in FibroGen in the second quarter valued at $128,000. Ameritas Investment Partners Inc. lifted its holdings in FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after acquiring an additional 696 shares during the period. SG Americas Securities LLC lifted its holdings in FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 412 shares during the period. Amalgamated Bank acquired a new stake in FibroGen in the second quarter valued at $237,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in FibroGen by 112.6% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 2,336 shares during the period. 57.43% of the stock is owned by institutional investors.
A number of equities research analysts have commented on FGEN shares. Jefferies Group reissued a “buy” rating and issued a $75.00 target price on shares of FibroGen in a report on Tuesday, September 12th. BidaskClub downgraded FibroGen from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Stifel Nicolaus reissued a “buy” rating and issued a $80.00 target price on shares of FibroGen in a report on Thursday, September 14th. Mizuho started coverage on FibroGen in a report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 target price for the company. Finally, ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $65.67.
In other news, Director Kalevi Kurkijarvi sold 12,000 shares of FibroGen stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $44.45, for a total transaction of $533,400.00. Following the completion of the transaction, the director now owns 36,000 shares of the company’s stock, valued at approximately $1,600,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gerald Lema purchased 3,500 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were purchased at an average cost of $46.70 per share, with a total value of $163,450.00. Following the purchase, the director now directly owns 3,500 shares in the company, valued at $163,450. The disclosure for this purchase can be found here. Insiders have sold a total of 326,595 shares of company stock valued at $17,364,822 in the last ninety days. Corporate insiders own 13.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://stocknewstimes.com/2017/12/14/40000-shares-in-fibrogen-inc-fgen-purchased-by-iguana-healthcare-management-llc.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.